Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02138786 · ClinicalTrials.gov registry record · Phase 2
Selinexor in Initial or Refractory and/or Relapsed Richter's Transformation
A Phase 2 study, sponsored by Karyopharm Therapeutics.
- Terminated
- Registry status
- Phase 2
- Development phase
- 27
- Enrollment target
NCT02138786 is a Phase 2 study that was terminated before completion, run by Karyopharm Therapeutics. The registered enrollment target is 27 participants.
The verdict
NCT02138786, a Phase 2 study, was terminated before completion, sponsored by Karyopharm Therapeutics.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 27 participants
- Enrollment target
Study Summary
This is a multi-center, phase 2, single arm, open-label study of oral selinexor monotherapy in patients with Richter's Transformation, arising in the setting of prior chronic lymphocytic leukemia (CLL), after at least one chemo-immunotherapy regimen for CLL.
Interventions
- DRUG selinexor
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 27 participants |
| Start Date | 2014-11-14 |
| Est. Completion | 2016-08-31 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02138786
The ClinicalTrials.gov registry entry for NCT02138786 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 27 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Karyopharm Therapeutics, which has 25 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which selinexor is the first listed.
NCT02138786 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02138786 about?
NCT02138786 is a clinical study titled "Selinexor in Initial or Refractory and/or Relapsed Richter's Transformation". This is a multi-center, phase 2, single arm, open-label study of oral selinexor monotherapy in patients with Richter's Transformation, arising in the setting of prior chronic lymphocytic leukemia (CLL), after at least one chemo-immunotherapy regimen for CLL.
What is the current status of trial NCT02138786?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 27 participants. The study started on 2014-11-14. Estimated completion is 2016-08-31.
What interventions are being tested in trial NCT02138786?
The interventions under investigation include: selinexor (DRUG).
Who is sponsoring clinical trial NCT02138786?
This trial is sponsored by Karyopharm Therapeutics, which has 25 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.